Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

319 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I study of the GM-CSF antagonist E21R.
Olver IN, Hercus T, Lopez A, Vadas M, Somogyi AA, Doyle I, Foster DJ, Keefe D, Taylor A, Brown M, To LB, Cole J, Rawling T, Cambareri B, Myers M, Olszewski N, Bastiras S, Senn C, Hey A, Verma M, Wigley P. Olver IN, et al. Cancer Chemother Pharmacol. 2002 Sep;50(3):171-8. doi: 10.1007/s00280-002-0474-y. Epub 2002 Jul 3. Cancer Chemother Pharmacol. 2002. PMID: 12203098 Clinical Trial.
Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436).
Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau HT, Brown MP, Hamid O, Infante JR, Millward M, Pavlick A, Chin MT, O'Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF. Falchook GS, et al. Among authors: brown mp. Clin Cancer Res. 2014 Sep 1;20(17):4449-58. doi: 10.1158/1078-0432.CCR-14-0887. Epub 2014 Jun 23. Clin Cancer Res. 2014. PMID: 24958809 Clinical Trial.
Phase II study evaluating efficacy and safety of everolimus with letrozole for management of advanced (unresectable or metastatic) non-small cell lung cancer after failure of platinum-based treatment: a preliminary analysis of toxicity.
Singhal N, Vatandoust S, Brown MP. Singhal N, et al. Among authors: brown mp. Cancer Chemother Pharmacol. 2015 Feb;75(2):325-31. doi: 10.1007/s00280-014-2644-0. Epub 2014 Dec 11. Cancer Chemother Pharmacol. 2015. PMID: 25502181 Clinical Trial.
Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma.
Gargett T, Abbas MN, Rolan P, Price JD, Gosling KM, Ferrante A, Ruszkiewicz A, Atmosukarto IIC, Altin J, Parish CR, Brown MP. Gargett T, et al. Among authors: brown mp. Cancer Immunol Immunother. 2018 Sep;67(9):1461-1472. doi: 10.1007/s00262-018-2207-z. Epub 2018 Jul 16. Cancer Immunol Immunother. 2018. PMID: 30014244 Free PMC article. Clinical Trial.
Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules.
Long GV, Robert C, Butler MO, Couture F, Carlino MS, O'Day S, Atkinson V, Cebon JS, Brown MP, Dalle S, Hill AG, Gibney GT, McCune S, Menzies AM, Niu C, Ibrahim N, Moreno BH, Diab A. Long GV, et al. Among authors: brown mp. Clin Cancer Res. 2021 Oct 1;27(19):5280-5288. doi: 10.1158/1078-0432.CCR-21-0793. Clin Cancer Res. 2021. PMID: 34210681 Free PMC article. Clinical Trial.
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).
Nathanson KL, Martin AM, Wubbenhorst B, Greshock J, Letrero R, D'Andrea K, O'Day S, Infante JR, Falchook GS, Arkenau HT, Millward M, Brown MP, Pavlick A, Davies MA, Ma B, Gagnon R, Curtis M, Lebowitz PF, Kefford R, Long GV. Nathanson KL, et al. Among authors: brown mp. Clin Cancer Res. 2013 Sep 1;19(17):4868-78. doi: 10.1158/1078-0432.CCR-13-0827. Epub 2013 Jul 5. Clin Cancer Res. 2013. PMID: 23833299 Free PMC article. Clinical Trial.
319 results